A Phase 2 interventional study of Patient-centered information and education in Olfactory Dysfunction and Wellbeing, sponsored by Monell Chemical Senses Center. Recruiting at 1 site in United States. Open to participants aged 7 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Monell Chemical Senses Center · Phase 2, Interventional, and Supportive care
Smell dysfunction is frequent yet neglected. The sense of smell plays a crucial role in signaling disease, safety, and overall quality of life. However, the significance of a functional sense of smell in terms of health and well-being is often overlooked until one experiences a loss of smell due to injury or disease. Research demonstrates that individuals are often not self-aware of their smell dysfunction (i.e. they do not spontaneously report smell dysfunction as a symptom), especially if the changes are gradual, as in normal aging. Patients with smell dysfunction experience a marked reduction in quality of life, poor mental health, nutritional health, and brain health as well as increased 5- and 10-year mortality in older adults. This study explores whether or not enabling healthcare providers to offer resources and guidance on coping strategies for smell dysfunction improves health and wellbeing in those who experience it.
The investigators will recruit participants in cycles for in person or remote participation. Each cycle is characterized by an initial assessment, intervention deployment (smell testing), post-intervention evaluation, 1-month and 6-month follow-ups via survey, text or phone to assess post-intervention psychological health and connection to care for smell dysfunction. The research team will assess odor detection, intensity, identification, pleasantness and discrimination. Based on the cut-offs determined prior to the beginning of data collection, the investigators will prospectively assign a participant to the smell dysfunction group or to the normosmia (no smell dysfunction) group. Based on this diagnostic intervention, participants with smell dysfunction will receive patient-centered information and education about i) community engagement with individuals with smell loss, ii) available counseling and iii) medical support. At the end of the 1-month and 6-month follow-up periods, the investigators will assess effectiveness of the intervention using pre-post comparisons to determine whether individuals taking a smell test felt improvements in their psychological health and whether they have contacted a provider and/or followed up with a visit.
Sessions may include multiple surveys/instruments depending on the session number. Specifically, emotional ratings and demographic information will be collected by means of either a paper - or computer-based questionnaire. A survey to measure psychological health and quality of life will be given to participants, as well as a questionnaire to measure depression, which is associated with smell dysfunction. Participants will answer questions about how they are feeling and how ready they are to contact a healthcare provider. The specific smell tests that will be given to participants will be either SCENTinel, NIH Toolbox, Arohma, or the B-SIT test. Other Follow-Up Questions include ones regarding access to care, contacting a provider, seeing a provider, and satisfaction with care.
70 studies on the registry are indexed under Olfaction Disorders; 18 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 60 across 49 interventional studies indexed under Olfaction Disorders.
Browse Olfaction Disorders studies →Monell Chemical Senses Center is the lead sponsor of 18 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Can read and understand English and have access to a reliable internet connection and a smart device or computer for the duration of the experimental sessions, unless they are part of community events in which smart devices are provided
Exclusion Criteria:
- Known intolerance or allergy to any of the odor stimuli used
Participants will take smell tests and receive educational materials on smell dysfunction.
Behavioral: Patient-centered information and education
No intervention
Participants with smell dysfunction will receive patient-centered information and education about i) community engagement with individuals with smell loss, ii) available counseling and iii) medical support.
Measuring depression symptoms using the PHQ-9 score
The PHQ-9 is a screening measure of depressive symptoms.
Time frame: PHQ-9 is completed at baseline, during 1 month follow-up session, and during the 6 month follow-up.
Measuring health-related quality of life using the SF-12 survey.
The SF-12 is a screening measure of health-related quality of life.
Time frame: SF-12 is completed at baseline, during 1 month follow-up session, and during the 6 month follow-up.
Measuring self-reported health perception using a "How do you feel?" 0-100 Visual Analogue Scale (VAS).
"How do you feel?" VAS is a self-reported measure of health perception.
Time frame: VAS is completed at baseline, during 1 month follow-up session, and during the 6 month follow-up.
Effectiveness of implementation (to contact a healthcare provider for smell dysfunction within up to 6 months from smell testing).
Participants are asked a Yes or No question about whether they contacted a healthcare provider. The investigators will examine the proportion of participants connecting with a healthcare provider for smell dysfunction.
Time frame: Evaluated during 1 month and 6 month follow ups
Plan to share: Yes — All collected data
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: When data collection begins, it will be uploaded to Hub4Smell and available for accessing following completion of data collection for every 250 participants. Once access to data on Hub4Smell has been granted, data will be available indefinitely.
Access criteria: Study subject data will be anonymized before data upload to the Hub4Smell database. The anonymization algorithm will be shared with the Hub4Smell Contributors by the Hub4Smell leadership team. Internally, Hub4Smell will associate a persistent surrogate key to identify each record. The study will include metadata attributes to define the data that will be shared with the Hub4Smell database. The Hub4Smell leadership team will trigger loading and sharing procedures of data to the Hub4Smell database. Data will be loaded privately and when marked ready to be shared, will become available to the Hub4Smell Contributors, who will be informed that a new batch of data has been uploaded. Consumers of the data will be required to create an account to download data. Access to source code will be controlled through GitHub user accounts. Access will be approved by the multiple principal investigators (MPIs) and technical teams. Data will be available indefinitely at this time.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Monell Chemical Senses Center